Evidence map›Paper›PMID 19303400›Full record

ArticleBiochemical and biophysical research communications2009

FAK mediates the inhibition of glioma cell migration by truncated 24 kDa FGF-2.

Amy H Lin, Brian P Eliceiri, Eugene G Levin

Abstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Amy H LinTorrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121, United States.
Brian P Eliceiri
Eugene G Levin
General Atomics (United States) · USTorrey Pines Institute For Molecular Studies · USUniversity of California, San Diego · US

Funding

Role of Src family kinases in endothelial cell biologyR01HL073396 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ELICEIRI, BRIAN P · 2002 to 2011
$3.5M
A Combinatorial Approach to Wound Healing for Protein, Gene and Cell TherapeuticsP20GM078421 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAIRD, ANDREW · 2006 to 2009
$3.4M
NHLBI NIH HHS R01 HL073396NIGMS NIH HHS P20 GM078421PHS HHS R01-081209
6 · The paper itself

Abstract

A truncated form of 24kDa FGF-2 consisting of 86 NH(2)-terminal amino acids (ATE+31) inhibits cell migration in vitro and tumor development and angiogenesis in vivo. Focal adhesion kinase (FAK) is phosphorylated on tyrosine and serine sites after cell stimulation by growth factors. This study examined the effect of ATE+31 on FAK phosphorylation in human glioma cells. FAK and Pyk phosphorylation were evaluated at serines known to be involved with cell migration. We demonstrated that ATE+31 at 3 x 10(-11)M decreases phosphorylation levels of Tyr(407)-FAK and Ser(732)-FAK in the presence of platelet-derived growth factor (PDGF), that ATE+31 in the presence of PDGF alters the distribution of FAK and other phosphotyrosine proteins in the adhesion contacts, and that ATE+31 in the presence of PDGF has no effect on the activation of Pyk2. These data suggest that the inhibition of cell migration by ATE+31 occurs via Tyr(407)-FAK and Ser(732)-FAK.

Indexed as

Cell Line, TumorCell MovementFibroblast Growth Factor 2Focal Adhesion Kinase 1Focal Adhesion Kinase 2GliomaHumansNeovascularization, PathologicPhosphorylationPhosphotyrosineSerineTyrosineFibroblast Growth Factor 2Focal Adhesion Kinase 1Focal Adhesion Kinase 2PhosphotyrosinePTK2 protein, humanSerineTyrosine

Identifiers

PMID19303400
PMCPMC3426351
OpenAlexW1992575830

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.